retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide for Obesity: Phase 2

Platforms that follow these principles earn higher patient ratings When platforms follow these principles, the payoff is better care and better outcomes

A: Neal: It got put in place as a temporary measure from Congress to try to bridge their way to another program called BALANCE

C., Amiel, S

healthcare landscape evolves, manufacturers who integrate PDTs into their market access strategy stand to gain a competitive advantage by aligning with evidence-driven, outcomes-based care models

For providers, high out-of-pocket costs and inconsistent coverage create real barriers to delivering optimal care

www.parkinson.org/living-with-parkinsons/treatment/exercise